TGFβ促进低产IL10的ILC2参与系统性硬化皮肤纤维化
该研究探索系统性硬化(SSc)皮肤纤维化中ILC2的功能与表型异质性。发现SSc皮肤中ILC2增多且与皮肤纤维化程度相关,TGFβ促进KLRG1- ILC2扩增并降低其IL10产生,增强促纤维化活性;小鼠模型中需联合吡非尼酮与IL10才能显著减轻皮肤纤维化。
要点
- SSc皮肤中ILC2数量增加且与皮肤纤维化程度相关。
- TGFβ促进KLRG1- ILC2扩增并降低IL10产生,增强促纤维化活性。
- 小鼠模型中联合吡非尼酮与IL10可显著减轻皮肤纤维化。
核心结论
- 天然ILC2通过TGFβ与IL10的相互作用参与SSc皮肤纤维化,为SSc提供新的治疗思路。
研究设计与样本
- 分析健康供者或SSc患者的血液样本和皮肤活检,采用免疫染色技术。
- 在体外将分选ILC2与真皮成纤维细胞共培养研究其促纤维化作用,并通过转录组学方法进一步探索。
- 在SSc小鼠模型中评估一种抗纤维化新疗法的疗效。
主要发现
- SSc患者皮肤中ILC2数量增加,且与皮肤纤维化范围相关。
- SSc皮肤中以KLRG1- ILC2(天然ILC2)为主,而非KLRG1+ ILC2(炎性ILC2)。
- TGFβ在SSc中活性增加,促进KLRG1- ILC2扩增,同时降低其IL10产生。
- IL10负向调控真皮成纤维细胞的胶原产生。
- TGFβ刺激的ILC2增加肌成纤维细胞分化,人KLRG1- ILC2具有增强的促纤维化活性。
关键数值与推荐
- 在SSc小鼠模型中,联合吡非尼酮与IL10的治疗干预减少皮肤浸润ILC2数量、增强其KLRG1表达并显著减轻皮肤纤维化。
临床怎么用
- SSc皮肤中ILC2增多且与纤维化程度相关,提示ILC2可作为潜在干预靶点。
- TGFβ降低ILC2产生IL10并增强其促纤维化活性,提示恢复IL10可能有益。
- 小鼠模型显示单用吡非尼酮不足以减轻纤维化,需联合IL10才能显著减轻皮肤纤维化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Innate lymphoid cells-2 (ILC2) were shown to be involved in the development of lung or hepatic fibrosis. We sought to explore the functional and phenotypic heterogeneity of ILC2 in skin fibrosis within systemic sclerosis (SSc). METHODS: Blood samples and skin biopsies from healthy donor or patients with SSc were analysed by immunostaining techniques. The fibrotic role of sorted ILC2 was studied in vitro on dermal fibroblast and further explored by transcriptomic approach. Finally, the efficacy of a new treatment against fibrosis was assessed with a mouse model of SSc. RESULTS: We found that ILC2 numbers were increased in the skin of patients with SSc and correlated with the extent of skin fibrosis. In SSc skin, KLRG1- ILC2 (natural ILC2) were dominating over KLRG1+ ILC2 (inflammatory ILC2). The cytokine transforming growth factor-β (TGFβ), whose activity is increased in SSc, favoured the expansion of KLRG1- ILC2 simultaneously decreasing their production of interleukin 10 (IL10), which regulates negatively collagen production by dermal fibroblasts. TGFβ-stimulated ILC2 also increased myofibroblast differentiation. Thus, human KLRG1- ILC2 had an enhanced profibrotic activity. In a mouse model of SSc, therapeutic intervention-combining pirfenidone with the administration of IL10 was required to reduce the numbers of skin infiltrating ILC2, enhancing their expression of KLRG1 and strongly alleviating skin fibrosis. CONCLUSION: Our results demonstrate a novel role for natural ILC2 and highlight their inter-relationships with TGFβ and IL10 in the development of skin fibrosis, thereby opening up new therapeutic approaches in SSc.
引用
- Laurent P, Allard B, Manicki P, et al. TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. Ann Rheum Dis. 2021. PMID: 34285051. doi:10.1136/annrheumdis-2020-219748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。